Estimating the economic effect of harm associated with high risk prescribing of oral non-steroidal anti-inflammatory drugs in England: population based cohort and economic modelling study

被引:0
|
作者
Camacho, Elizabeth M. [1 ]
Penner, Leonie S. [1 ]
Taylor, Amy [2 ,3 ]
Guthrie, Bruce [4 ]
Avery, Anthony J. [2 ,3 ]
Ashcroft, Darren M. [3 ,5 ]
Morales, Daniel R. [6 ,7 ]
Rogers, Gabriel [1 ]
Chuter, Antony [1 ,3 ]
Elliott, Rachel A. [1 ,3 ]
机构
[1] Univ Manchester, Manchester Ctr Hlth Econ, Div Populat Hlth Hlth Serv Res & Primary Care, Manchester, England
[2] Univ Nottingham, Ctr Acad Primary Care, Sch Med, Nottingham, England
[3] NIHR Greater Manchester Patient Safety Res Collabo, Manchester, England
[4] Univ Edinburgh, Usher Inst, Adv Care Res Ctr, Edinburgh, Scotland
[5] Univ Manchester, Fac Biol Med & Hlth, Ctr Pharmacoepidemiol & Drug Safety, Sch Hlth Sci, Manchester, England
[6] Univ Dundee, Populat Hlth & Genom, Dundee DD1 4HN, Scotland
[7] Univ Southern Denmark, Dept Publ Hlth, Odense, Denmark
来源
BMJ-BRITISH MEDICAL JOURNAL | 2024年 / 386卷
基金
美国国家卫生研究院;
关键词
INFORMATION-TECHNOLOGY INTERVENTION; COST-EFFECTIVENESS; COMPLICATIONS; IMPACT; SAFETY; STRATEGIES; ARTHRITIS; ERRORS;
D O I
10.1136/bmj-2023-077880
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES To quantify prevalence, harms, and NHS costs in England of problematic oral non-steroidal antiinflammatory drug (NSAID) prescribing in high risk groups. DESIGN Population based cohort and economic modelling study. SETTING Economic models estimating patient harm associated with NSAID specific hazardous prescribing events, and cost to the English NHS, over a 10 year period, were combined with trends of hazardous prescribing event to estimate national levels of patient harm and NHS costs. PARTICIPANTS Eligible participants were prescribed oral NSAIDs and were in five high risk groups: older adults (>= 65 years) with no gastroprotection; people who concurrently took oral anticoagulants; or those with heart failure, chronic kidney disease, or a history of peptic ulcer. MAIN OUTCOME MEASURES Prevalence of hazardous prescribing events, by each event and overall, discounted quality adjusted life years (QALYs) lost, and cost to the NHS in England of managing harm. RESULTS QALY losses and cost increases were observed for each hazardous prescribing event (v no hazardous prescribing event). Mean QALYs per person were between 0.01 (95% credibility interval (CI) 0.01 to 0.02) lower with history of peptic ulcer, to 0.11 (0.04 to 0.19) lower with chronic kidney disease. Mean cost increases ranged from a non-statistically significant 14 pound (<euro>17; $18) (95% CI -71 pound to 98) pound in heart failure, to a statistically significant 1097 pound (236 pound to 2542) pound in people concurrently taking anticoagulants. Prevalence of hazardous prescribing events per 1000 patients ranged from 0.11 in people who have had a peptic ulcer to 1.70 in older adults. Nationally, the most common hazardous prescribing event (older adults with no gastroprotection) resulted in 1929 (1416 to 2452) QALYs lost, costing 2.46m pound (0.65m pound to 4.68m) pound. The greatest impact was in people concurrently taking oral anticoagulants: 2143 (894 to 4073) QALYs lost, costing 25.41m pound (5.25m pound to 60.01m) pound. Over 10 years, total QALYs lost were estimated to be 6335 (4471 to 8658) and an NHS cost for England of 31.43m pound (9.28m pound to 67.11m) pound. CONCLUSIONS NSAIDs continue to be a source of avoidable harm and healthcare cost in these five high risk populations, especially in inducing an acute event in people with chronic condition and people taking oral anticoagulants.
引用
收藏
页数:9
相关论文
共 24 条
  • [11] Clinical and economic implications of upper gastrointestinal adverse events in Asian rheumatological patients on long-term non-steroidal anti-inflammatory drugs
    Pok, Lydia Say Lee
    Shabaruddin, Fatiha Hana
    Dahlui, Maznah
    Sockalingam, Sargunan
    Mohamed Said, Mohd Shahrir
    Rosman, Azmillah
    Lau, Ing Soo
    Isa, Liza Mohd
    Hussein, Heselynn
    Ng, Chin Teck
    Mahadeva, Sanjiv
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (05) : 943 - 951
  • [12] Charting the Knowledge and Patterns of Non-Steroidal Anti-Inflammatory Drugs Usage in Hail Population, Saudi Arabia: Insights into the Adverse Effect Profile
    Altahini, Abdullah T.
    Aburas, Waled
    Aljarwan, Saud F.
    Alsuwayagh, Suliman A.
    Alqahtani, Naif F.
    Alquwaiay, Saleh
    Anwar, Sirajudheen
    PHARMACY, 2024, 12 (01)
  • [13] Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: a case-control study
    Etminan, M.
    Levesque, L.
    Fitzgerald, J. M.
    Brophy, J. M.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 29 (11) : 1188 - 1192
  • [14] Do aspirin and non-steroidal anti-inflammatory drugs increase the risk of post-sphincterotomy hemorrhage - A case-control study
    Onal, Ibrahim Koral
    Parlak, Erkan
    Akdogan, Meral
    Yesil, Yusuf
    Kuran, Sedef Ozdal
    Kurt, Mevlut
    Disibeyaz, Selcuk
    Ozturk, Eda
    Odemis, Bulent
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2013, 37 (02) : 171 - 176
  • [15] Postoperative use of non-steroidal anti-inflammatory drugs in patients with anastomotic leakage requiring reoperation after colorectal resection: cohort study based on prospective data
    Klein, Mads
    Gogenur, Ismail
    Rosenberg, Jacob
    BMJ-BRITISH MEDICAL JOURNAL, 2012, 345
  • [16] Risk of cardiovascular diseases and gastrointestinal bleeding is comparable between celecoxib and non-selective non-steroidal anti-inflammatory drugs in patients with ankylosing spondylitis: a nationwide retrospective cohort study
    Kim, A.
    Kim, S. C.
    Kim, J.
    So, M. W.
    Lee, S. -G
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2025, : 204 - 212
  • [17] Aspirin and other non-steroidal anti-inflammatory drugs and depression, anxiety, and stress-related disorders following a cancer diagnosis: a nationwide register-based cohort study
    Hu, Kejia
    Sjolander, Arvid
    Lu, Donghao
    Walker, Adam K.
    Sloan, Erica K.
    Fall, Katja
    Valdimarsdottir, Unnur
    Hall, Per
    Smedby, Karin E.
    Fang, Fang
    BMC MEDICINE, 2020, 18 (01)
  • [18] Gastrointestinal events in at-risk patients starting non-steroidal anti-inflammatory drugs (NSAIDs) for rheumatic diseases: the EVIDENCE study of European routine practice
    Lanas, Angel
    Boers, Maarten
    Nuevo, Javier
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (04) : 675 - 681
  • [19] A cluster randomised stepped wedge trial to evaluate the effectiveness of a multifaceted information technology-based intervention in reducing high-risk prescribing of non-steroidal anti-inflammatory drugs and antiplatelets in primary medical care: The DQIP study protocol
    Dreischulte, Tobias
    Grant, Aileen
    Donnan, Peter
    McCowan, Colin
    Davey, Peter
    Petrie, Dennis
    Treweek, Shaun
    Guthrie, Bruce
    IMPLEMENTATION SCIENCE, 2012, 7
  • [20] Association of peri-operative prescription of non-steroidal anti-inflammatory drugs with continued prescription of opioids after total knee arthroplasty: a retrospective claims-based cohort study
    Hussain, N.
    Brull, R.
    Gilron, I.
    Weaver, T. E.
    Shahzad, H.
    D'Souza, R. S.
    Abdel-Rasoul, M.
    Clarke, H.
    McCartney, C. J. L.
    Abdallah, F. W.
    ANAESTHESIA, 2024, 79 (07) : 725 - 734